Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
about
Transglutaminase is a tumor cell and cancer stem cell survival factorFibronectin matrix assembly suppresses dispersal of glioblastoma cellsCellular functions of tissue transglutaminaseSmall molecule inhibitors target the tissue transglutaminase and fibronectin interactionAn in-solution ultrasonication-assisted digestion method for improved extracellular matrix proteome coverageDependence of invadopodia function on collagen fiber spacing and cross-linking: computational modeling and experimental evidence.Clinical and biological significance of tissue transglutaminase in ovarian carcinoma.Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells.Novel chemo-sensitizing agent, ERW1227B, impairs cellular motility and enhances cell death in glioblastomasExtracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury.Transglutaminase regulation of cell function.Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.Microarray-based transcriptional and epigenetic profiling of matrix metalloproteinases, collagens, and related genes in cancer.Transglutaminase 2 expression is increased as a function of malignancy grade and negatively regulates cell growth in meningioma.Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma.Phosphorylation of transglutaminase 2 (TG2) at serine-216 has a role in TG2 mediated activation of nuclear factor-kappa B and in the downregulation of PTENRGD-independent cell adhesion via a tissue transglutaminase-fibronectin matrix promotes fibronectin fibril deposition and requires syndecan-4/2 α5β1 integrin co-signalingTissue transglutaminase mediates the pro-malignant effects of oncostatin M receptor over-expression in cervical squamous cell carcinoma.Characterization of transglutaminase type II role in dendritic cell differentiation and function.Transglutaminase 2: a molecular Swiss army knife.Transglutaminase 2 is secreted from smooth muscle cells by transamidation-dependent microparticle formation.Reduction in gap junction intercellular communication promotes glioma migration.NG2 proteoglycan-dependent recruitment of tumor macrophages promotes pericyte-endothelial cell interactions required for brain tumor vascularization.Transglutaminase 2 inhibitors and their therapeutic role in disease states.Ataxia-Telangiectasia, Mutated (ATM)/Nuclear Factor κ light chain enhancer of activated B cells (NFκB) signaling controls basal and DNA damage-induced transglutaminase 2 expression.Tissue transglutaminase-interleukin-6 axis facilitates peritoneal tumor spreading and metastasis of human ovarian cancer cells.R(h)oads to microvesiclesTissue transglutaminase: a new target to reverse cancer drug resistanceNG2 Proteoglycan-Dependent Contributions of Pericytes and Macrophages to Brain Tumor Vascularization and Progression.Transglutaminase 2 cross-linking activity is linked to invadopodia formation and cartilage breakdown in arthritis.A comparison of epithelial-to-mesenchymal transition and re-epithelializationRhoA triggers a specific signaling pathway that generates transforming microvesicles in cancer cells.The Different Conformational States of Tissue Transglutaminase Have Opposing Affects on Cell Viability.Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling.TGM2 inhibition attenuates ID1 expression in CD44-high glioma-initiating cellsRole of collagen matrix in tumor angiogenesis and glioblastoma multiforme progression.Tissue transglutaminase is an essential participant in the epidermal growth factor-stimulated signaling pathway leading to cancer cell migration and invasionMeasuring brain tumor growth: combined bioluminescence imaging-magnetic resonance imaging strategy.Transglutaminase activation in neurodegenerative diseases.Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters.
P2860
Q26799862-AD20F950-07A9-4CC1-A61F-34C11ECEBD1BQ27320106-615FCD27-D5D8-46FB-A527-D50A6B0A0F27Q28260600-0DF9EAFF-B5B1-404A-9E6A-516341E89B84Q28540004-29534A3F-0B66-4968-817E-FD85CF5929E7Q30480813-AA526E87-0E52-4C42-9EC3-F06BF8AF457BQ30483094-CA75B4D1-300F-4095-A911-0DC2C5A43C43Q30483685-4FC0E5F7-8D25-4F41-BCA1-542EA93C9CDFQ30499127-BED8AF8C-3FFA-4C9B-BB1C-7C91976AF15FQ30542102-C61A9633-73BF-4C9B-B0CF-056E77B517B6Q33325485-756D76FA-D5B6-46C8-81E1-7F2BE90BDFEEQ33707936-4AC0FCF6-4078-4C47-A033-0987D8308BE1Q33728989-53DE93CC-7447-45F7-87E2-E2EA84A84E32Q33911466-6DDEE405-1A21-4F2A-BBA5-D206B9B377F6Q34233236-83F27FA0-C59C-49AB-8F0C-BD26EDDEE76DQ34251059-9AAF1828-04B8-4A65-B4C7-D306456C84F6Q34324624-67B5DD3B-27D0-4900-9073-4F63E15AA378Q34401105-ED37AF81-33C6-4411-B371-AEBA4EC87356Q34891045-B8DC4ED8-7B8A-4F30-AF9B-16A1A713524DQ35534802-377738E7-4D71-4408-A9DA-139E378D52CAQ35693361-355A7413-C73B-40F4-94C1-D6CAD1C14AC1Q35697155-4E015F83-3CC8-4C1E-A252-E03D0E61C5ECQ35793827-82FD483E-F970-42FF-BFD3-490B61042C0AQ35799099-545A6AE4-5652-4738-BAA6-E0BE043C444DQ35989247-FA2BB953-42AD-43C7-B6A6-F1F8F21A47BFQ36003028-DC67F775-C7FE-4A00-BF19-FECBC5E6EC19Q36447849-52FA0FED-802B-47FD-8F99-EA1C63060800Q36463007-538EBB94-B53D-4C7F-B8FD-0FC44B528533Q36503511-33607D57-BD41-473B-AEA9-64A6F2DA2478Q36552576-92456E2B-70FA-408E-B009-9887F27AC39BQ36633284-138AA006-5358-4723-968D-9DB0C8EB12ECQ36678367-84DEE479-A63A-4E03-A1CE-A5320F4FB2C5Q36713922-D4F23450-D78E-4091-9EC8-2F1A0CEC2BD2Q36884822-45882D23-4F43-4ECE-ADDE-41336428969CQ36916874-47FC2CFE-CC76-468D-9011-338B6197D2BFQ37187694-44971E75-052E-42D2-87D3-EA800BB4B4A5Q37218231-446DE6A0-2A4C-4BEB-A60C-D594BB361018Q37258496-FB5E3E6A-38B1-4AE8-916E-FD21703468ADQ37317888-9677B9CC-7A89-42E6-A863-7594820D766CQ37352964-9252FE28-E47B-4C79-980F-1E87A0C7E0E2Q37620999-2BDEDAD4-99E9-48A3-BE05-C164CAC0D8B1
P2860
Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Transglutaminase 2 inhibitor, ...... glioblastomas to chemotherapy.
@en
Transglutaminase 2 inhibitor, ...... glioblastomas to chemotherapy.
@nl
type
label
Transglutaminase 2 inhibitor, ...... glioblastomas to chemotherapy.
@en
Transglutaminase 2 inhibitor, ...... glioblastomas to chemotherapy.
@nl
prefLabel
Transglutaminase 2 inhibitor, ...... glioblastomas to chemotherapy.
@en
Transglutaminase 2 inhibitor, ...... glioblastomas to chemotherapy.
@nl
P2093
P356
P1433
P1476
Transglutaminase 2 inhibitor, ...... glioblastomas to chemotherapy
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.ONC.1210048
P407
P577
2006-11-13T00:00:00Z